Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Salivary Gland Neoplasms 1Neoplasm Metastasis 1Metastatic Non-small Cell Lung Cancers 1Lung Neoplasms 1Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 34Specimen Handling 18Paclitaxel 16Magnetic Resonance Spectroscopy 15Carboplatin 14Biopsy 14Nivolumab 13Ipilimumab 12Gemcitabine 10Irinotecan 9Radiosurgery 8atezolizumab 7abemaciclib 7Radiation 7Pemetrexed 7Cisplatin 7Capecitabine 7130-nm albumin-bound paclitaxel 7trastuzumab deruxtecan 6olaparib 6durvalumab 6avelumab 6Docetaxel 6osimertinib 5adagrasib 5Trastuzumab 5Fulvestrant 5Cetuximab 5Albumin-Bound Paclitaxel 5palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm Metastasis × amivantamab × Clear all
NCT05117931 2026-02-17

A Study of Amivantamab in People With Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
25 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡